Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD
Abstract
:1. Introduction
2. Materials and Methods
Study Design
3. Results
3.1. Characteristics of Respondents
3.2. Pharmacists’ Knowledge Regarding Donepezil AEs
3.3. Pharmacists’ Knowledge Regarding Self-Care Recommendations
4. Discussion
5. Conclusions
Supplementary Materials
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Alzheimer’s Association. 2017 Alzheimer’s Disease Facts and Figures. Available online: http://preview.alz.org/ri/documents/facts2017_report(1).pdf (accessed on 2 June 2017).
- Swerdlow, R.H. Pathogenesis of Alzheimer's disease. Clin. Interv. Aging 2007, 2, 347–359. [Google Scholar] [PubMed]
- Alzheimer Disease International. Policy Brief: The Global Impact of Dementia 2013–2050; Alzheimer Disease International: London, UK, 2013; Available online: https://www.alz.co.uk/research/GlobalImpactDementia2013.pdf (accessed on 30 March 2017).
- Aricept (Donepezil Hydrochloride) Tablets Package Insert. Eisai Inc. (updated 2015). Available online: http://labeling.pfizer.com/ShowLabeling.aspx?id=510 (accessed on 18 May 2017).
- Razadyne (Galantamine Hydrobromide) Tablets Package Insert. Janssen Pharmaceuticals, Inc. (updated 2013). Available online: http://www.janssen.com/us/sites/www_janssen_com_usa/files/products-documents/razadyne_er_1.pdf (accessed on 18 May 2017).
- Exelon (Rivastigmine Tartrate) Capsules Package Insert. Novartis Pharmaceuticals Corporation (updated 2015). Available online: http://pharma.us.novartis.com/product/pi/pdf/exelon.pdf (accessed on 18 May 2017).
- Exelon (Rivastigmine Transdermal System) Patch Package Insert. Novartis Pharmaceuticals Corporation (updated February 2015). Available online: http://www.pharma.us.novartis.com/product/pi/pdf/exelonpatch.pdf (accessed on 18 May 2017).
- Namenda (Memantine HCl) Tablets for Oral Use, Package Insert. Forest Pharmaceuticals, Inc. (updated October 2013). Available online: https://www.allergan.com/assets/pdf/namenda_pi (accessed on 18 May 2017).
- Doody, R.S.; Stevens, J.C.; Beck, C.; Dubinsky, R.M.; Kaye, J.A.; Gwyther, L.; Mohs, R.C.; Thal, L.J.; Whitehouse, P.J.; DeKosky, S.T.; et al. Practice Parameter: Management of Dementia (an Evidence-Based Review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001, 56, 1154–1166. [Google Scholar] [CrossRef] [PubMed]
- Tricco, A.C.; Vandervaart, S.; Soobiah, C.; Lillie, E.; Perrier, L.; Chen, M.H.; Hemmelgarn, B.; Majumdar, S.R.; Straus, S.E. Efficacy of cognitive enhancers for Alzheimer’s disease: Protocol for a systemic review and network meta-analysis. Syst. Rev. 2012, 1, 31. [Google Scholar] [CrossRef] [PubMed]
- Morrison, C.M.; Glover, D.; Gilchrist, S.M.; Casey, M.O.; Lanza, A.; Lane, R.I.; Patanian, M. A Program Guide for Public Health: Partnering with Pharmacists in the Prevention and Control of Chronic Diseases. National Center for Chronic Disease Prevention and Health Promotion, 2012. Available online: http://www.cdc.gov/dhdsp/programs/spha/docs/pharmacist_guide.pdf (accessed on 15 June 2017).
- Giberson, S.; Yoder, S.; Lee, M.P. Improving Patient and Health System Outcomes through Advanced Pharmacy Practice: A Report to the U.S. Surgeon General. 2011. Available online: http://www.accp.com/docs/positions/misc/improving_patient_and_health_system_outcomes.pdf (accessed on 8 June 2017).
- Skelton, J.B. White paper on expanding the role of pharmacists in caring for individuals with Alzheimer’s disease: APhA Foundation Coordinating Council to Improve Collaboration in Supporting Patients with Alzheimer’s Disease. J. Am. Pharm. Assoc. 2008, 48, 715–721. [Google Scholar] [CrossRef] [PubMed]
- United States Census Bureau. Available online: https://www.census.gov/quickfacts/table/PST045216/38 (accessed on 10 May 2017).
- Stafford, A. The pharmacist’s role in supporting people living with dementia in the community. Aust. Pharm. 2015, 34. Available online: http://www.detectearly.org.au/wp-content/uploads/2015/02/The-pharmacists-role-in-supporting-people-living-with-dementia.pdf (accessed on 8 June 2017).
- Rickles, N.M.; Skelton, J.B.; Davis, J.; Hopson, J. Cognitive memory screening and referral program in community pharmacies in the United States. Int. J. Clin. Pharm. 2014, 36, 360–367. [Google Scholar] [CrossRef] [PubMed]
- Manolakis, P.G.; Skelton, J.B. Pharmacists’ contributions to primary care in the United States collaborating to address unmet patient care needs: The emerging role for pharmacists to address the shortage of primary care providers. Am. J. Pharm. Educ. 2010, 74, S7. [Google Scholar] [CrossRef] [PubMed]
- Marvanova, M.; Henkel, P. Community pharmacists’ knowledge of Alzheimer’s disease care in high- and low-income Chicago. J. Am. Pharm. Assoc. 2017. [Google Scholar] [CrossRef] [PubMed]
- Zerafa, N.; Scerri, C. Knowledge and pharmacological management of Alzheimer’s disease by managing community pharmacists: A nationwide study. Int. J. Clin. Pharm. 2016, 38, 1416–1424. [Google Scholar] [CrossRef] [PubMed]
- Barry, H.E.; Parsons, C.; Passmore, A.P.; Hughes, C.M. Community pharmacists and people with dementia: A cross-sectional survey exploring experiences, attitudes, and knowledge of pain and its management. Int. J. Geriatr. Psychiatry 2013, 28, 1077–1085. [Google Scholar] [CrossRef] [PubMed]
- Hemberg, N.; Huggins, D.; Michaels, N.; Moose, J. Innovative Community Pharmacy Practice Models in North Carolina. N. C. Med. J. 2017, 78, 198–201. [Google Scholar] [CrossRef] [PubMed]
- Kelling, S.E.; Rondon-Begazo, A.; DiPietro Mager, N.A.; Murphy, B.L.; Bright, D.R. Provision of Clinical Preventive Services by Community Pharmacists. Prev. Chronic Dis. 2016, 13, E149. [Google Scholar] [CrossRef] [PubMed]
- Campbell, N.L.; Perkins, A.J.; Gao, S.; Skaar, T.C.; Li, L.; Hendrie, H.C.; Fowler, N.; Callahan, C.M.; Boustani, M.A. Adherence and Tolerability of Alzheimer’s Disease Medications: A Pragmatic Randomized Trial. J. Am. Geriatr. Soc. 2017, 65, 1497–1504. [Google Scholar] [CrossRef] [PubMed]
- Gardette, V.; Andrieu, S.; Lapeyre-Mestre, M.; Coley, N.; Cantet, C.; Ousset, P.J.; Grand, A.; Monstastruc, J.L.; Vellas, B. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer's disease: A 2-year prospective, multicentre, cohort study. CNS Drugs 2010, 24, 431–442. [Google Scholar] [CrossRef] [PubMed]
- Arlt, S.; Lindner, R.; Rösler, A.; von Renteln-Kruse, W. Adherence to medication in patients with dementia: Predictors and strategies for improvement. Drugs Aging 2008, 25, 1033–1047. [Google Scholar] [CrossRef] [PubMed]
- Umegaki, H.; Itoh, A.; Suzuki, Y.; Nabeshima, T. Discontinuation of donepezil for the treatment of Alzheimer’s disease in geriatric practice. Int. Psychogeriatr. 2008, 20, 800–806. [Google Scholar] [CrossRef] [PubMed]
- Nanaumi, Y.; Onda, M.; Tsubota, K.; Tanaka, R.; Mukai, Y.; Matoba, S.; Tanaka, Y.; Arakawa, Y. Effectiveness of Pharmacists’ Comprehensive Assessment of Medication Profiles in Dementia Patients. Yakugaku Zasshi 2015, 135, 1057–1067. [Google Scholar] [CrossRef] [PubMed]
- Nanaumi, Y.; Matoba, S.; Onda, M.; Tanaka, R.; Tsubota, K.; Mukai, Y.; Sakurai, H.; Hayase, Y.; Arakawa, Y. Pilot study of dementia medication compliance conducted among pharmacists providing home visits which evaluates the degree of drug compliance, as defined by numerous attributes, between patients at home and patients in a medical facility. Yakugaku Zasshi 2012, 132, 387–393. [Google Scholar] [CrossRef] [PubMed]
- Watanabe, N.; Yamamura, K.; Suzuki, Y.; Umegaki, H.; Shigeno, K.; Matsushita, R.; Sai, Y.; Miyamoto, K.; Yamada, K. Pharmacist-based Donepezil Outpatient Consultation Service to improve medication persistence. Patient Prefer Adherence 2012, 6, 605–611. [Google Scholar] [PubMed]
- Sverdrup Efjestad, A.; Ihle-Hansen, H.; Hjellvik, V.; Blix, H.S. Comedication and Treatment Length in Users of Acetylcholinesterase Inhibitors. Demen Geriatr. Cogn. Dis. Extra 2017, 7, 30–40. [Google Scholar] [CrossRef] [PubMed]
- American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults. J. Am. Geriatr. Soc. 2015, 63, 2227–2246. [Google Scholar]
- Ghezzi, L.; Scarpini, E.; Galimberti, D. Disease-modifying drugs in Alzheimer’s disease. Drug Des. Dev. Ther. 2013, 7, 1471–1478. [Google Scholar]
- Hogan, D.B.; Bailey, P.; Black, S.; Carswell, A.; Chertkow, H.; Clarke, B.; Cohen, C.; Fisk, J.D.; Forbes, D.; Man-Son-Hing, M.; et al. Diagnosis and treatment of dementia: 5. Nonpharmacologic and pharmacologic therapy for mild to moderate dementia. CMAJ 2008, 179, 1019–1026. [Google Scholar] [CrossRef] [PubMed]
- Kogut, S.J.; El-Maouche, D.; Abughosh, S.M. Decreased persistence to cholinesterase inhibitor therapy with concomitant use of drugs that can impair cognition. Pharmacotherapy 2005, 25, 1729–1735. [Google Scholar] [CrossRef] [PubMed]
- Blokland, A. Acetylcholine: A neurotransmitter for learning and memory? Brain Res. Rev. 1995, 21, 285–300. [Google Scholar] [CrossRef]
- Schroeck, J.L.; Ford, J.; Conway, E.L.; Kurtzhalts, K.E.; Gee, M.E.; Vollmer, K.A.; Mergenhagen, K.A. Review of Safety and Efficacy of Sleep Medicines in Older Adults. Clin. Ther. 2016, 38, 2340–2372. [Google Scholar] [CrossRef] [PubMed]
- Lefebvre, T.; Foster, B.C.; Drouin, C.E.; Krantis, A.; Livesey, J.F.; Jordan, S.A. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J. Pharm. Pharm. Sci. 2004, 7, 265–773. [Google Scholar] [PubMed]
- Saeed, Y.; Abbott, S.M. Circadian Disruption Associated with Alzheimer's Disease. Curr. Neurol. Neurosci. Rep. 2017, 17, 29. [Google Scholar] [CrossRef] [PubMed]
- Salami, O.; Lyketsos, C.; Rao, V. Treatment of sleep disturbance in Alzheimer's dementia. Int. J. Geriatr. Psychiatry 2011, 26, 771–782. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.H.; Swaab, D.F. Disturbance and strategies for reactivation of the circadian rhythm system in aging and Alzheimer’s disease. Sleep Med. 2007, 8, 623–636. [Google Scholar] [CrossRef] [PubMed]
- Asayama, K.; Yamadera, H.; Ito, T.; Suzuki, H.; Kudo, Y.; Endo, S. Double blind study of melatonin effects on the sleep-wake rhythm, cognitive and non-cognitive functions in Alzheimer type dementia. J. Nippon. Med. Sch. 2003, 70, 334–341. [Google Scholar] [CrossRef] [PubMed]
- McCleery, J.; Cohen, D.A.; Sharpley, A.L. Pharmacotherapies for sleep disturbances in dementia. Cochrane Database Syst. Rev. 2016. [Google Scholar] [CrossRef]
- Kachru, N.; Carnahan, R.M.; Johnson, M.L.; Aparasu, R.R. Potentially inappropriate anticholinergic medication use in older adults with dementia. J. Am. Pharm. Assoc. 2015, 55, 603–612. [Google Scholar] [CrossRef] [PubMed]
- Bhattacharya, R.; Chatterjee, S.; Carnahan, R.M.; Aparasu, R.R. Prevalence and predictors of anticholinergic agents in elderly outpatients with dementia. Am. J. Geriatr. Pharmacother. 2011, 9, 434–441. [Google Scholar] [CrossRef] [PubMed]
- Abraham, O.; Schleiden, L.; Albert, S.M. Over-the-counter medications containing diphenhydramine and doxylamine used by older adults to improve sleep. Int. J. Clin. Pharm. 2017. [Google Scholar] [CrossRef] [PubMed]
Characteristic | n | % |
---|---|---|
Sex | ||
Male | 434 | 50.3% |
Female | 428 | 47.7% |
Pharmacy Terminal Degree | ||
Bachelor of Science in Pharmacy | 375 | 43.5% |
Doctor of Pharmacy | 487 | 56.5% |
Study Areas | ||
Northern California | 119 | 13.8% |
Southern Oregon | 58 | 6.7% |
North Dakota | 109 | 12.7% |
South Dakota | 156 | 18.1% |
West Virginia | 420 | 48.7% |
Knowledge of AEs | Mean | SD |
---|---|---|
Common AEs a | 1.17 | 1.27 |
Number of AEs Named | N | % |
≥ 1 AEs | 513 | 61.7% |
≥ 2 AEs | 261 | 31.4% |
≥ 3 AEs | 131 | 15.7% |
Common Adverse Effects a | n | % |
Nausea | 311 | 36.1% |
Diarrhea | 129 | 15.0% |
Headache | 33 | 3.8% |
Vomiting | 120 | 13.9% |
Insomnia | 55 | 6.4% |
Anorexia | 57 | 6.6% |
Dizziness | 216 | 25.1% |
Muscle Cramps | 12 | 1.4% |
Weight Loss | 14 | 1.6% |
Fatigue | 26 | 3.0% |
Other Adverse Effects b | n | % |
Bradycardia c | 5 | 0.6% |
Vivid Dreams | 10 | 1.2% |
Recommendation | n | % |
---|---|---|
APPROPRIATE | 542 | 62.9% |
Melatonin | 347 | 40.3% |
Refer to Physician | 190 | 22.0% |
Sleep Hygiene | 5 | 0.6% |
INAPPROPRIATE | 107 | 12.4% |
Anticholinergic Agent a | 104 | 12.1% |
Valerian Root | 3 | 0.4% |
DON’T KNOW | 185 | 21.5% |
REFUSE | 28 | 3.3% |
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Marvanova, M.; Henkel, P.J. Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD. Pharmacy 2017, 5, 42. https://doi.org/10.3390/pharmacy5030042
Marvanova M, Henkel PJ. Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD. Pharmacy. 2017; 5(3):42. https://doi.org/10.3390/pharmacy5030042
Chicago/Turabian StyleMarvanova, Marketa, and Paul Jacob Henkel. 2017. "Community Pharmacists’ Knowledge Regarding Donepezil Averse Effects and Self-Care Recommendations for Insomnia for Persons with AD" Pharmacy 5, no. 3: 42. https://doi.org/10.3390/pharmacy5030042